ReviewCurrent heart failure reports2026
Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe review potential applications and pitfalls of urinary biomarkers in people with heart failure (HF). RECENT
findingsAlbuminuria may indicate kidney damage and guide prioritization of medications in HF. Urine sodium is useful in guiding diuretic management. Several experimental urine biomarkers have been evaluated, with the most robust data available for neutrophil gelatinase-associated lipocalin, kidney injury marker 1, insulin-like growth factor-binding protein 7 in conjunction with tissue inhibitor of metalloproteinases-2, angiotensinogen, and N-acetyl-β-D-glucosaminidase. None provide diagnostic superiority over serum creatinine in evaluating risk of kidney injury. Some may have utility in identifying those at risk for adverse clinical outcomes. While urine albumin and sodium have prognostic and diagnostic utility in HF, the current role for other urine biomarkers is less clear, particularly in predicting worsening kidney function. Some of these biomarkers may provide mechanistic insights into kidney damage in HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.